MLTX - MoonLake Immunotherapeutics
18.14
0.450 2.481%
Share volume: 655,381
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$17.69
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-07-2024 | 11-07-2024 | 02-26-2025 | 05-12-2025 | 11-05-2025 | 02-25-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 19.820 M | 30.578 M | 43.112 M | 49.580 M | 47.485 M | 71.434 M | 65.217 M | |
| Selling general and admin | 6.806 M | 6.916 M | 7.376 M | 9.221 M | 11.026 M | 10.799 M | 9.211 M | |
| Research and development | 13.014 M | 23.662 M | 35.736 M | 40.360 M | 36.459 M | 60.635 M | 56.006 M | |
| Total expenses | 19.820 M | 30.578 M | 43.112 M | 49.580 M | 47.485 M | 71.434 M | 65.217 M | |
| 54.28% | 40.99% | 15.00% | -4.23% | 50.43% | -8.70% | |||
| Operating income | -19.820 M | -30.578 M | -43.112 M | -49.580 M | -47.485 M | -71.434 M | -65.217 M | |
| Ebit | -13.905 M | -24.680 M | -36.022 M | -46.355 M | -40.388 M | -67.381 M | -60.774 M | |
| Pretax income | -13.905 M | -24.680 M | -36.022 M | -46.355 M | -40.406 M | -70.579 M | -62.769 M | |
| 77.49% | 45.96% | 28.68% | -12.83% | 74.67% | -11.07% | |||
| Income tax | 70.252 K | 78.701 K | 92.106 K | 41.140 K | 153.000 K | 115.000 K | 248.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -13.976 M | -24.759 M | -36.114 M | -46.396 M | -40.559 M | -70.694 M | -63.017 M | |
| -77.16% | -45.87% | -28.47% | 12.58% | -74.30% | 10.86% |